JMP Securities analyst Roy Buchanan reiterated a Buy rating on PolyPid (PYPD – Research Report) today and set a price target of $16.00. The company’s shares opened today at $6.01.
According to TipRanks, Buchanan is an analyst with an average return of -10.8% and a 30.86% success rate. Buchanan covers the Healthcare sector, focusing on stocks such as PolyPid, Enanta Pharmaceuticals, and Arbutus Biopharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for PolyPid with a $21.50 average price target.
See the top stocks recommended by analysts >>
Based on PolyPid’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $11.87 million. In comparison, last year the company had a GAAP net loss of $8.69 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PolyPid Ltd was incorporated under the laws of Israel and commenced its operations on February 28, 2008. The Company is a clinical stage specialty pharmaceutical company engaged in research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the Company’s proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, BonyPid-1000, BonyPid-500, PLEX, and D-PLEX are trademarks of the Company. The Company is subject to extensive regulation by the FDA, under the Federal Food, Drug, and Cosmetic Act, as well as by other federal, state, and local regulatory agencies.
Read More on PYPD:
- Rackspace Technology Enables Konesh Mission Critical Operation for Certified Accounting and Tax Management
- TOMI Advances SteraMist Disinfection in the Food Safety Industry
- Zynerba Pharmaceuticals (ZYNE) Gets a Hold from Needham
- HII Marks Milestone in Virginia-Class Submarine Massachusetts (SSN 798) Construction
- Genmab Announces Financial Results for the First Half of 2022
